Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference

01 Jun 2018 - 04 Jun 2018

Nassau, Bahamas

Synopsis

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planned conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets or approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries, including presentations of clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases.  

Key topics of discussion will include:
1) BACE1 inhibitors and/or γ-secretase modulators for reducing amyloid deposition 
2) active and passive vaccination for enhancing clearance of amyloid plaques
3) Vaccines for reducing tau pathology
4) Antisense approaches for AD, PD and ALS therapy
5) Neural stem cell approaches for neurodegeneration
6) Inflammatory modulators for neurodegeneration.

The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together and to discuss the latest advances and the future challenges in the field.  It will also facilitate interactions between junior scientists and leading investigators in a relatively small conference setting. 

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the earlybird rate of $1,823 and bring a student for only $850. Unfortunately, Postdocs are not eligible. Both registration packages include; accommodation for the 01, 02, 03 June 2018 (on a shared basis for students) and a 24hour all-inclusive food and beverage package for the conference period. Once registered, please contact Jack Peters (jack@fusion-conferences.com) to obtain a special registration link for your student.

Plenary Speakers

David Holtzman (Washington University)
Li-Huei Tsai (MIT) 

Invited Speakers

Elizabeth M. Bradshaw (Center for translational & Computational Neuroimmunology Columbia University Medical Center)
Matt Blurton-Jones
(University of California, Irvine)
Guy Brown (University of Cambridge) 
Guojun Bu
(Mayo Clinic)
Rita Cacace (University of Antwerp)
Damian Crowther (AstraZeneca)
Philip De Jager (Center for translational & Computational Neuroimmunology Columbia University Medical Center)
Charles Glabe (University of California, Irvine)
Yadong Huang (Gladstone Institute)
Sally Ishizaka (Eisai) 
Orly Lazarov (University of Illinois at Chicago)
Yueming Li (Memorial Sloan Kettering Cancer Center)
Richard Mayeux (Taub Institute at Columbia University)
Jennifer Pocock (University College London)
Domenico Praticò (Temple University)
Nikolaos Robakis (Mount Sinai)
Gerard D. Schellenberg (University of Pennsylvania Perelman School of Medicine)
Sangram S. Sisodia (The University of Chicago)
Giulio Taglialatela (University of Texas Medical Branch)
Giuseppinna Tesco (Tufts University)
Taisuke Tomita
(University of Tokyo)
Jeffery M. Vance (University of Miami)
Robert Vassar (Northwestern University)
Huaxi Xu (Sanford Burnham Prebys Medical Discovery Institute)
Gang Yu (UT Southwestern)
Xiongwei Zhu (Case Western Reserve University)

Sponsors

Sponsors

Report

The first Fusion Conference on ‘Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases’ was held in Nassau, Bahamas from 1st to 4th June, 2018.  The conferenced attracted scientists from countries around the world such as; the USA, Canada, UK, Belgium, and Japan.  

In the inaugural keynote lecture, Dr. David Holtzman from Washington University first presented a historical overview of apolipoprotein ApoE, the most well studied risk gene in association with the late onset of Alzheimer’s disease, and then discussed most recent discoveries on the role of ApoE in the control of tau aggregation. Dr. Li-Huei Tsai from Massachusetts Institute of Technology presented another plenary lecture on the topic of how microglia are activated in response to the challenge of neurodegeneration at the resolution of single cell levels and how LED lights, flicking at certain wavelength, activate microglia to engulf amyloid plaques. Both lectures received considerable attentions in the audience and discussions. 

Almost all speakers in the conference presented outstanding lectures and discussed large portions of results that are not yet published. The programme had many standout talks across the four days. Dr. Yadong Huang from Gladstone Institute at UCSF investigated the effect of ApoE isoforms in IPSCs-derived neurons on synaptic dysfunctions and reported how to block ApoE4 toxicity through a chemical perturbation based on the difference of 3D structure of ApoE4 vs ApoE3. Dr. Mathew Blurton-Jones compared functional genomic datasets between iPSC-derived microglia from human and AD mouse models and identified unique signatures at different disease stages. Dr. Riqiang Yan from University of Connecticut health presented a not yet published finding that the C-terminal of CX3CL1 controls neurogenesis in the adult and increased expression of this fragment will reverse neuronal loss in a tau mouse model.  Dr. Richard Mayeux from Columbia University discussed mutations of certain genes that are preferentially associated with certain racial groups. Ultra-rare mutations in SCRAP and FBXL7 are found to occur more frequently in the Caribbean Hispanic population while AKAP9 is a risk factor for the Africa American population. This study is important as it reveals race-dependent risky genes that are not easily seen in conventional genetic studies using whole genome populations. Dr. Philip L De Jager, another investigator from the Columbia University, presented large network dataset constructed from over four hundred individuals’ RNA seq results and identified gene modules unique to AD and related neuropathologies. One example is that upregulation of module 5 genes is associated with increased tau protein aggregation and accumulation, which correlates with declines in cognitive function. His data analyses also captured genes from activated microglia that are clustered in AD but less obvious in multiple sclerosis. Dr. Charles Glabe from UC Irvine discussed a captivating observation that amyloid plaques in one AD mouse model, 5xFAD model, evolve from intra neurons rather than the conventional thought of extra neuronal seeding theory. Chemical ablation of microglia will prevent formation of amyloid deposition. Dr. Sally Ishizaka, Director of the Immuno-Dementia Division at Eisai presented the strategy for human genetic-guided drug discovery for AD patients.  

Two junior fellows, Drs. Cara Croft from University of Florida and Rita Cacace from University of Antwerp, also gave outstanding presentations.  Cara reported the first in vitro 3D model for monitoring the progression of tau aggregation and fibrillary tangles while Rita discussed how chrosome 7q36 is associated with late onset of AD and revealed DPP6 is a candidate genes for AD, frontal temporal dementia based on their human and mouse genetic studies. Both talks won lengthy discussions from audience and their answers to these questions were satisfying and enlightening.   

One of the most memorable components of the meeting was the active discussion after each presentation and during the refreshment breaks. There were many pressing questions and lengthy debates. One vehement argument, was even resolved through WWE-style fake fighting!  

Many of the conference attendees not only contributed outstanding lectures but also recognized the need for a continuing conference in such a format.  It was agreed by many that this conference has created a collegial format where attendees can have close interactions with each other and discuss the most important and updated scientific questions in the Alzheimer’s field. Holding this conference every two years is necessary as finding a cure for AD patients is so urgent and more efforts and funding resources are needed in order to enable this. 

We would like to acknowledge the Conference sponsors and media partners; Eisai Ltd, Fusion Conferences, Alzheimer Disease & Associated Disorders and the Journal of Alzheimer's Disease. Without their support it would have been impossible to have held such a wonderful conference.

Conference Chairs Dr. Riqiang Yan and Dr. Peter St George-Hyslop, along with Plenary speaker Dr. Li-Huei Tsai, are currently deciding on a location and date for the second meeting. Once confirmed, all details will be released on this webpage and via Fusion Conferences’ social media.
A forthcoming meeting that may be of interest is the 2nd Neurogenesis Conference, being held from March 5th-8th 2019 in Nassau, Bahamas. Oral and poster submissions are currently being accepted. 

Programme

FRIDAY 1st JUNE 2018

14:00 – 14:45

Registration & Reception

14:00 – 14:45

Group Welcome Lunch

14:45 – 15:00

Opening Comments

PERSPECTIVES OF AD PATHOGENESIS
Riqiang Yan and Peter St George-Hyslop

15:00 – 15:45

David Holtzman Washington University in St. Louis

APOE: ROLE IN AMYLOID-β ACCUMULATION AND IN TAU-MEDIATED NEURODEGENERATION

15:45 – 16:00

Zhengui Xia
University of Washington

GENE-ENVIRONMENT INTERACTION BETWEEN LEAD AND APOLIPOPROTEIN E4 CAUSES COGNITIVE BEHAVIOR DEFICITS IN MICE

16:00 – 16:30

Guojun Bu
Mayo Clinic

PATHOBIOLOGY AND THERAPEUTIC TARGETING OF APOE IN ALZHEIMER’S DISEASE

16:30 – 17:00

Sangram Sisodia
University of Chicago

MODULATION OF AMYLOID DEPOSITION AND NEUROINFLAMMATION BY THE MICROBIOME

17:00 – 17:30

Refreshments

STEM CELLS IN AD
Peter St. George-Hyslop

17:30 – 18:00

Orly Lazarov
University of Illinois at Chicago

THERAPEUTIC AND DIAGNOSTIC POTENTIAL OF CREB IN ALZHEIMER’S DISEASE

18:00 – 18:30

Mathew Blurton-Jones
University of California, Irvine

USING iPSC-DERIVED MICROGLIA AND HUMANIZED MICE TO STUDY THE FUNCTIONAL GENOMICS OF ALZHEIMER'S DISEASE

18:30 – 19:00

Yadong Huang
Gladstone Institute

ALZHEIMER'S DISEASE MODELING AND DRUG SCREENING USING HUMAN IPSCS

19:00 – 19:30

Giulio Taglialatela
University of Texas Medical Branch at Galveston

NEURAL STEM CELLS PROMOTE SYNAPTIC RESILIENCE TO DAMAGING Ab AND TAU OLIGOMERS VIA EXOSOME DELIVERY OF SELECTED MIRNA CARGOES

19:30 – 20:00

Riqiang Yan
University of Connecticut

ENHANCING NEUROGENESIS TO REVERSE NEURONAL LOSS IN AD MOUSE MODELS

20:00

Group Dinner

SATURDAY 2nd JUNE 2018

07:00 – 08:30

Breakfast

GENETICS AND EPIGENETICS OF AD
Nikolaos Robakis

08:30 – 09:00

Gerard Schellenberg
University of Pennsylvania Perelman School of Medicine

GENETIC STUDIES OF ALZHEIMER'S DISEASE; IDENTIFICATION OF THERAPEUTIC TARGETS

09:00 – 09:30

Jeffery Vance
University of Miami Health System

IDENTIFYING A PROTECTIVE FACTOR FOR APOE4

09:30 – 10:00

Richard Mayeux
Taub Institute at Columbia University

GENETIC AND GENOMIC CONTRIBUTIONS TO ALZHEIMER’S DISEASE FROM THE CARIBBEAN ISLANDS

10:00 – 10:30

Rita Cacace
University of Antwerp

EXPLORING THE MISSING GENETICS OF EARLY ONSET ALZHEIMER’S DISEASE: INSIGHTS FROM GENOMIC STUDIES IN AUTOSOMAL DOMINANT FAMILIES

10:30

Group Photo & Refreshments

10:45 – 16:15

Free Time

12:30 – 15:00

Snorkel Trip (Signups required in advance)

MOLECULAR MECHANISM OF AD PATHOGENESIS
Guojun Bu

16:15 – 16:45

Peter St George-Hyslop
University of Toronto

PHYSIOLOGICAL AND PATHOLOGICAL PHASE SEPARATION OF FUS IS REGULATED BY METHYLATION OF COOPERATIVE CROSS-DOMAIN CATION-PI INTERACTIONS AND INTERACTION WITH TNPO1

16:45 – 17:15

Domenico Praticò
Temple University

THE LEUKOTRIENES PATHWAY AS A VIABLE THERAPEUTIC TARGET FOR TAUOPATHIES

17:15 – 17:45

Charles Glabe
University of California, Irvine

PLX3397, A CSF1R/C-KIT INHIBITOR, ABLATES MICROGLIA AND BLOCKS THE ACCUMULATION OF INTRANEURONAL AMYLOID AND NEURITIC PLAQUES IN 5XFAD MICE

17:45 – 18:15

Refreshments

18:15 – 18:30

Cara Croft
University of Florida

rAAV-MEDIATED BRAIN SLICE CULTURE MODELS TO DEVELOP TAU-BASED THERAPEUTICS

18:30 – 19:00

Sally Ishizaka
Eisai

IMMUNO-DEMENTIA: HUMAN GENETICS-GUIDED DRUG DISCOVERY IN ALZEIMER'S DISEASE

19:00 – 19:30

Taisuke Tomita
University of Tokyo

NOVEL STRATEGIES FOR FACILITATION OF AMYLOID CLEARANCE IN THE BRAIN

19:30

Group Dinner

SUNDAY 3rd JUNE 2018

07:00 – 08:30

Breakfast

NEURO-INFLAMMATION IN AD
Robert Vassar

08:30 – 09:15

Li-Huei Tsai
MIT

DECIPHERING THE IMMUNE RESPONSE OF MICROGLIA IN NEURODEGENERATION USING SINGLE-CELL RNA-SEQUENCING

09:15 – 09:45

Guy Brown
University of Cambridge

NEURODEGENERATION CAUSED BY MICROGLIAL PHAGOCYTOSIS OF NEURONS

09:45 – 10:15

Elizabeth M. Bradshaw
Center for translational & Computational Neuroimmunology, Columbia University Medical Center

ARE CD33 SIALIC-ACID DEPENDENT BINDING PARTNERS THERAPEUTIC TARGETS FOR AD?

10:15 – 10:45

Refreshments

10:45 – 11:15

Damian Crowther
AstraZeneca

TREM2 METABOLISM AT THE CELL SURFACE: OPTIONS FOR THERAPEUTIC MODULATION

11:15 – 11:45

Jennifer Pocock
University College London

TREM2 VARIANTS; RAMIFICATIONS FOR MICROGLIAL FUNCTION

11:45 – 12:15

Philip L. De Jager
Center for translational & Computational Neuroimmunology, Columbia University Medical Center

POPULATION STRUCTURE OF HUMAN MICROGLIA: WHICH SUBSET OF MICROGLIA DO WE TARGET FOR TAU AND/OR AMYLOID PATHOLOGY?

12:15 – 17:30

Lunch at Leisure & Free Time

SECRETASES IN AD THERAPY
Huaxi Hu

17:30 – 18:00

Robert Vassar
Northwestern University

BACE1 AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE

18:00 – 18:15

Brati Das
University of Connecticut Health Center

DELETION OF BACE1 IN ADULT AD MICE REVERSES AMYLOID DEPOSITION AND IMPROVES SYNAPTIC FUNCTION

18:15 – 18:45

Giuseppina Tesco
Tufts University

BACE1 UPS AND DOWNS: IMPLICATIONS FOR AD

18:45 – 19:15

Yueming Li
Memorial Sloan Kettering Institute

HYPOXIA AND GAMMA-SECRETASE

19:45

*Gala Dinner*

MONDAY 4th JUNE 2018

07:00 – 08:30

Breakfast

NOVEL TARGETS IN AD THERAPY
Charles Glabe

08:30 – 09:00

Huaxi Xu
Sanford Burnham Prebys Medical Discovery Institute

NOVEL ROLES FOR ALZHEIMER’S RISK GENE SORLA IN NEUROPROTECTION

09:00 – 09:30

Nikolaos Robakis
Mount Sinai School of Medicine

PS1-REGULATED NEUROPROTECTIVE NMDAR COMPLEXES ARE INACTIVATED BY FAD MUTANTS

09:30 – 10:00

Gang Yu
UT Southwestern

GAMMA-SECRETASE, GLIA/IMMUNE FUNCTION, AND ALZHEIMER’S DISEASE?

10:00 – 10:30

Refreshments

10:30 – 10:45

Ronald Davis
Scripps Research Institute Florida

SMALL MOLECULE PROBES TARGETING NEURONAL MITOCHONDRIAL DYNAMICS INCREASE ATP PRODUCTION, RESCUE OXIDATIVE STRESS AND AMYLOID BETA MEDIATED NEUROTOXICITY

10:45 – 11:15

Xiongwei Zhu
Case Western Reserve University

ABNORMAL MITOCHONDRIAL DYNAMICS AS A THERAPEUTIC TARGET OF ALZHEIMER DISEASE

11:15 – 11:30

Closing Comments by Peter St. George-Hyslop and Riqiang Yan

Speakers

Plenary Speakers

  • Dr. David Holtzman
    Professor and Chair, Washington University in St. Louis
  • Dr. Li-Huei Tsai
    Professor and Director, MIT

Invited Speakers

  • Prof. Dr. Taisuke Tomita
    Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • Prof. Domenico Pratico
    Professor, Temple University
  • Dr. Sally Ishizaka
    Director, Immuno-Dementia, Eisai Inc.
  • Dr. Mathew Blurton-Jones
    Associate Professor, University of California, Irvine
  • Prof. Orly Lazarov
    Professor, The University of Illinois at Chicago
  • Dr. Charles Glabe
    Professor, UC Irvine
  • Prof. Guojun Bu
    Professor, Mayo Clinic
  • Prof. Gerard Schellenberg
    Professor, Perelman School of Medicine, University of Pennsylvania
  • Dr. Giuseppina Tesco
    Associate Professor, Tufts University
  • Prof. Dr. Robert Vassar
    Professor, Northwestern University
  • Prof. Gang YU
    Professor, University of Texas Southwestern Medical Center
  • Dr. Nikolaos Robakis
    Professor, Mount Sinai Medical Cemter
  • Prof. Xiongwei Zhu
    Professor, Case Western Reserve University
  • Dr. Elizabeth Bradshaw
    Assistant Professor, Center for translational & Computational Neuroimmunology Columbia University Medical Center
  • Dr. Damian Crowther
    Director, R&D, Neuroscience, AstraZeneca IMED Biotech Unit
  • Prof. Dr. Giulio Taglialatela
    Professor and Vice Chair, University of Texas Medical Branch
  • Prof. Guy Brown
    Professor, University of Cambridge
  • Dr. Rita Cacace
    Postdoc, University of Antwerp
  • Prof. Dr. Huaxi Xu
    Professor and Director of Neuroscience, Sanford Burnham Prebys Medical Discovery Institute
  • Prof. Yueming Li
    Professor, Memorial Sloan Kettering Cancer Center
  • Prof. Dr. Yadong Huang
    Senior Investigator/Professor, Gladstone Institutes/UCSF
  • Prof. Dr. Richard Mayeux
    Professor, Taub Institute at Columbia University
  • Prof. Dr. Jeff Vance
    professor, University of Miami
  • Dr. Jennifer Pocock
    Senior Lecturer, University College London Institute of Neurology
  • Prof. sangram sisodia
    Professor of Neurosciences, university of chicago
  • Prof. Philip De Jager
    Professor of Neurology, Columbia University Medical Center

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr